Last reviewed · How we verify
methylprednisolone IV — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
methylprednisolone IV (methylprednisolone IV) — Rennes University Hospital. Methylprednisolone binds to glucocorticoid receptors, suppressing inflammatory mediators and immune cell activity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| methylprednisolone IV TARGET | methylprednisolone IV | Rennes University Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- methylprednisolone IV CI watch — RSS
- methylprednisolone IV CI watch — Atom
- methylprednisolone IV CI watch — JSON
- methylprednisolone IV alone — RSS
Cite this brief
Drug Landscape (2026). methylprednisolone IV — Competitive Intelligence Brief. https://druglandscape.com/ci/methylprednisolone-iv. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing